Key facts
- Pheon Therapeutics’s last known valuation is $172.7M.
- It has raised $191.1M; the latest was Later Stage VC ($119.9M) in May 2024.
- Notable investors include Lightspeed Venture Partners, Forbion, Perceptive Advisors, Hostplus Superannuation Fund, Atlas Venture — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Pheon Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Pheon Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pheon Therapeutics
Developer of advanced cancer treatment intended for targeting hard-to-treat cancers. The company leverages antibody drug conjugates to develop next-generation treatments, utilizing both novel and clinically validated monoclonal antibodies armed with proprietary payloads, enabling healthcare market to address unmet medical needs in solid tumors and liquid cancers through innovative and effective therapies.
- Sector
- Healthcare
- HQ
- United Kingdom
- Founded
- 2015
- Employees
- 29
- Website
- pheontx.com/
- Ownership
- Privately Held (backing)
Pheon Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pheon Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pheon Therapeutics in its N-PORT filings yet. We sweep new filings monthly.